Cameron McDonough
Directeur Général chez GENERATION BIO CO.
Fortune : 5 M $ au 30/04/2024
Postes actifs de Cameron McDonough
Sociétés | Poste | Début | Fin |
---|---|---|---|
GENERATION BIO CO. | Directeur/Membre du Conseil | 01/10/2017 | - |
Directeur Général | 01/10/2017 | - | |
President | 01/10/2017 | - | |
THIRD HARMONIC BIO, INC. | Directeur/Membre du Conseil | 28/03/2024 | - |
Independent Dir/Board Member | 28/03/2024 | - | |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | - | - |
Historique de carrière de Cameron McDonough
Anciens postes connus de Cameron McDonough
Sociétés | Poste | Début | Fin |
---|---|---|---|
SURFACE ONCOLOGY, INC. | Directeur/Membre du Conseil | 22/02/2018 | 28/02/2022 |
Independent Dir/Board Member | 22/02/2018 | 28/02/2022 | |
PTC THERAPEUTICS, INC. | Directeur/Membre du Conseil | 06/11/2012 | 18/09/2017 |
Independent Dir/Board Member | 06/11/2012 | 18/09/2017 | |
SWEDISH ORPHAN BIOVITRUM AB | Directeur Général | 15/08/2011 | 22/05/2017 |
President | 15/08/2011 | 22/05/2017 | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/2002 | - |
Catalyst Medical Solutions, Inc. | Fondateur | - | - |
President | - | - | |
LARIMAR THERAPEUTICS, INC. | Directeur/Membre du Conseil | 28/09/2015 | - |
Independent Dir/Board Member | 28/09/2015 | - |
Formation de Cameron McDonough
Harvard Medical School | Graduate Degree |
The University of North Carolina at Chapel Hill | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 11 |
Suède | 2 |
Opérationnelle
Director/Board Member | 5 |
Independent Dir/Board Member | 4 |
President | 3 |
Sectorielle
Health Technology | 8 |
Consumer Services | 3 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 4 |
---|---|
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
PTC THERAPEUTICS, INC. | Health Technology |
GENERATION BIO CO. | Health Technology |
THIRD HARMONIC BIO, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Zafgen, Inc.
Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Catalyst Medical Solutions, Inc. | |
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
- Bourse
- Insiders
- Cameron McDonough
- Expérience